Comparative Pharmacology
Head-to-head clinical analysis: ERELZI versus YUSIMRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERELZI versus YUSIMRY.
ERELZI vs YUSIMRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human IgG1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
YUSIMRY (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, reducing inflammatory responses.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
Subcutaneous: 200 mg every 2 weeks. For patients with body weight ≥100 kg, consider 200 mg every week. IV: 300 mg as a loading dose on day 1, then 200 mg every 2 weeks subcutaneously.
None Documented
None Documented
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Terminal elimination half-life ranges from 10 to 20 days (mean ~14 days) in adults; consistent with IgG1 monoclonal antibody clearance. Reduced half-life may be observed in patients with high tumor burden or concomitant methotrexate.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Elimination occurs via reticuloendothelial system with catabolism into amino acids; no significant renal or biliary excretion of intact adalimumab. Mean renal excretion of adalimumab is <1% of dose as intact monoclonal antibody.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor